

2022 SAPA-GP Annual  
Conference

**TURBO  
CHARGING  
INNOVATION  
IN THE NEW  
DECADE OF LIFE  
SCIENCES**

April 15 - 16, 2022  
Sheraton Valley Forge Hotel 480 N  
Gulph Rd, King of Prussia, PA 19406



# Greetings from President Office

Dear SAPA-GP Members and Friends:

It is our great pleasure to welcome you to the Annual Conference of the Sino-American Pharmaceutical Professionals Association – Greater Philadelphia (SAPA-GP). This is also the celebration of the twentieth anniversary of our organization.

We would like to thank you for supporting SAPA-GP during the past two challenging years of Covid-19 epidemic. In doing so, you support the life sciences community also help advance pharmaceutical sciences and technologies. Among 3000+ worldwide registrants, it was exciting to have many of you in our 20+ webinars, which covered diverse topics ranging from career development to legal, regulatory, and business. One of our key missions is to foster and nurture the growth of our young and talented members. Our mentorship program, led by Dr. David Cragin and his team, has continued its success by increasing the number of mentee-mentor pairs by 7-fold and offering by many career webinars and networking events. We continued to promote and enhance the diversity and inclusion in our team and connect our talent pool to many pharma and biotech organizations. We further strengthened collaborations across SAPA's many chapters.

We are proud to present this year's Annual Conference with topics covering cutting-edge research and development. This includes medicines to combat COVID-19, innovations in preclinical development and CMC, and career development. This 1 ½-day in-person and virtual hybrid event offers a wonderful platform for you to interact with top researchers, entrepreneurs, investors, recruiters, human resource specialists, lawyers, and government officials. In addition, we are extremely excited to announce our new program, @PHILLY, which will be a world-leading meeting on cell and gene therapy on June 16-17<sup>th</sup>, 2022.

And kudos to our leadership teams, executive office members, and volunteers for their outstanding dedication and contributions. We want to express our gratitude to our sponsors, speakers, friends, and family members of GP for your tremendous support in helping us build life sciences in the Greater Philadelphia area. Together, we are creating a strong life sciences ecosystem. Together with the global pharmaceutical and healthcare communities, we are shaping the future of pharmaceutical research and development and making our world healthier and better!

Enjoy the conference, stay healthy, and best wishes for continued success!

SAPA GP President Office:



Yongchao Su  
President  
(2021-2022)



Fang Shen  
President Immediate  
Past (2020-2021)



Haichen Yang  
President-Elect  
(2022-2023)



Yang Yuan  
President-Elect  
(2023-2024)

## Day 1: April 15th, 1:00-5:00 p.m., Friday

1:00-1:15 pm

Opening Remarks & SAPA-GP 20-Year Celebration *Yang Yuan* (**Grand Ballroom**)

1:15-2:00 pm

Plenary Session: A New Era of Vaccinology: COVID and Beyond *Shan Lu* (**Grand Ballroom**)

2:00-2:15 pm

Coffee Break

2:15-4:00 pm

**Scientific Track (**Grand Ballroom**)**  
Redefining pharmaceutical innovation from bench to bedside

**Session 1: Beating COVID with Pivoting Science: Implication for Future Diagnostic and Therapeutic Development**

- *Discovery Therapeutic for PAN COVID19 Variants - Zhuoming Liu*
- *COVID19 testing and genomic sequencing/assay kit dev. – ZiXuan Wang*

**Business Track (**Centennial Ballroom**)**

Unleashing the power from scientific breakthroughs and entrepreneurship

**Session 1: Maximizing shareholders value in changing market environment**

- *Seamus Jiang, Managing Director, China/US. Cross-border deals Leader, PwC US*
- *Derrick Li, Managing Director, Baird*
- *Geert Cauwenbergh, Founder & Senior Managing Partner, Phases123, LLC*

4:00-5:00 pm

Networking and reception

## Day 2: April 16th, 8:30-5:00 p.m., Saturday

8:30-9:45 am

Plenary session: Latest Advances in Development of Therapeutic Treatment (**Grand Ballroom**)

9:45-10:00 am

Coffee Break

10:00 am-12:00 pm

**Session 2: Nonclinical development and CMC: New Strategies and Innovative Approaches for Novel Modalities**

- *Managing Organic Impurities through Deep Understanding of Chemistry and Innovative Analytical Solutions - Yong Liu*
- *mRNA-based vaccines: Non-Clinical Safety Assessment Strategy - Yun Zhang*
- *Considerations of Establishing Comparability for Lipid Nanoparticle Products Containing siRNA – Julia Gao*

**Session 2: Transitioning from a scientist to an entrepreneur: steps and lessons in starting the first company**

- *Lora Feng, Founder & CEO, LFI Solutions*
- *Xi Qin, COO/CFO of NeuExcell Therapeutics*
- *Bin Yuan, CEO & Co-founder, OnCusp Therapeutics*
- *Lily Zou, Cofounder & CEO, Degron Therapeutics*
- *Louis Liu, Attorney and Partner of Liu, Chen & Hoffman LLP*
- *Stella Xu, Managing Director, Quan Capital*

12:00-1:00 pm

Lunch Break & Meet-in-Person Session, SAPA GP's Mentor/Mentee program (by invitation only)

1:00-3:00 pm

**Session 3: Innovation in *Clinical Trials***

- *The Promise of Digital Health: from Clinical Trials to Clinical Practice - Alex Morozov*
- *Reimagining Neuroscience Drug Development Using a Digital Companion Strategy - Vinay Parikh*
- *Data Science Driven Acceleration of the J&J Covid-19 Vaccine Phase III Trial - Jennings Xu*

**Session 3: Building and growing a life science company (co-branding with BioKatalyst) (**Centennial Room I**)**

- *Seamus Jiang, Managing Director, China/US. Cross-border deals Leader, PwC US*
- *Yuhang Zhao, SVP of China Grand Enterprises*
- *Jimmy Hao, Partner, Fox Rothschild*
- *Dahai Guo, Chairman and CEO, Zennova Pharma*
- *Joanne Jiang, CEO, LeaderMed Group*

**Career development (**Centennial Room II&III**)**

**Marie Leithauser & David Cragin**  
**Do you need an executive coach? Come to learn how:**

- *To create deep trust and rapport*
- *Coaching is different than mentoring*
- *To develop a strong executive elevator speech*
- *In addition, networking with old friends and make new ones*

3:00-5:00 pm

Networking and reception

## AGENDA

**Day 1: April 15<sup>th</sup>, 1:00-5:00 p.m.(EDT), Friday**

**1:00-1:15 p.m. Opening Remarks & SAPA-GP 20-Year Celebration** **Grand Ballroom**

**Yang Yuan**, President-Elect of SAPA-GP 2023-2024; Sr Principal Scientist, Bristol Myers Squibb

**Plenary Session: A New Era of Vaccinology: COVID and Beyond** **Grand Ballroom**

**Session chair** **Yongchao Su**, President of SAPA-GP 2021-2022; Principal Scientist, Merck & Co., Inc.

**1:15-2:00 p.m.** **Shan Lu**, Professor, Department of Medicine, University of Massachusetts

**2:00-2:15 p.m.** **Coffee Break**

**Scientific Track: Redefining Pharmaceutical Innovation: from Bench to Bedside** **Grand Ballroom**

**Beating COVID with Pivoting Science: Implication for Future Diagnostic and Therapeutic Development**

**Session chairs** **Jian (Jason) He**, CMC lead, Senior Director, WuXi Biologics

**Jun He**, Assistant professor, Thomas Jefferson University

**2:15-2:50 p.m.** **Zhuoming Liu**, Faculty Instructor, School of Medicine, Washington University in St. Louis

“Discovery Therapeutics for Pan COVID19 Variants”

**2:50-3:25 p.m.** **Zi-Xuan (Zoe) Wang**, Associate Professor, Thomas Jefferson University

“COVID19 Testing and Genomic Sequencing in an Academic Molecular Lab in the Midst of Pandemic”

**Business Track: Unleashing the Power from Scientific Breakthroughs and Entrepreneurship** **Centennial Ballroom I**

**Maximizing Shareholders Value in Changing Market Environment (co-branding with BioKatalyst)**

**Session chair** **Seamus Jiang**, Managing Director, China/US. Cross-border deals Leader, PwC US

**2:15-4:00 p.m.** **Derrick Li**, Managing Director, Baird

**Geert Cauwenbergh**, Founder & Senior Managing Partner, Phases123, LLC

Panel discussion

**4:00-5:00 p.m. Networking & Reception**

## AGENDA

**Day 2: April 16th, 8:30-5:00 p.m. (EDT), Saturday**

### Plenary Session: Latest Advances in Development of Therapeutic Treatment **Grand Ballroom**

- Session chair** Fang Shen, President Immediate-Past of SAPA-GP (2020-2021), VP, Research & Translational biology, Immunome
- 8:30-9:45 a.m.** Jingsong Wang, Founder, Chairman & CEO, Harbour BioMed  
“Leveraging Industry Leading Technology Platforms to Build Next-gen Novel Therapeutics”  
Chris Chen, CEO, WuXi Biologics  
“Developing Covid-19 Therapeutic mabs at the Speed of Light”
- Panel Discussion** James Fendrick, President & CEO, Rockland Immunochemicals  
Chris Chen, CEO, WuXi Biologics  
Jingsong Wang, Founder, Chairman & CEO, Harbour BioMed
- 9:45-10:00 a.m.** Coffee break

### Scientific Track: Redefining Pharmaceutical Innovation from Bench to Bedside

**Grand Ballroom**

#### Nonclinical development and CMC: New Strategies and Innovative Approaches for Novel Modalities

- Session chairs** Ying-Ying Zhou, Senior Principal Scientist, Merck & Co., Inc.  
Yan Yuan, Professor, University of Pennsylvania
- 10:00-10:35 a.m.** Yong Liu, Senior Principal Scientist, Merck & Co., Inc.  
“Managing Organic Impurities through Deep Understanding of Chemistry and Innovative Analytical Solutions”
- 10:35-11:10 a.m.** Yun Zhang, Drug Safety Team Lead, Global Portfolio Safety, Pfizer Inc.  
“mRNA-Based Vaccines: Non-Clinical Safety Assessment Strategy”
- 11:10-11:45 a.m.** Julia Gao, Director, CMC Team Leadership, Bristol Myers Squibb  
“Considerations of Establishing Comparability for Lipid Nanoparticle Products Containing siRNA”

### Business Track: Unleashing the Power from Scientific Breakthroughs and Entrepreneurship

**Centennial Ballroom I**

#### Transitioning from a Scientist to an Entrepreneur: Steps and Lessons in Starting the First Company

- Session chair** Lora Feng, Founder & CEO, LFI Solutions
- 10:00-12:00 p.m.** Bin Yuan, CEO & Co-founder, OnCusp Therapeutics
- Panel Discussion** Lily Zou, Cofounder & CEO, Degron Therapeutics  
Xi Qin, COO & CFO of NeuExcell Therapeutics  
Louis Liu, Founder & Partner, Liu, Chen & Hoffman LLP

Stella Xu, Managing Director, Quan Capital

**12:00-1:00 p.m.** **Lunch Break** (lunch provided to in-person attendees)

**12:00-1:00 p.m.** **Meet-in-Person Session, SAPA GP's Mentor/Mentee program (by invitation only)**

## Scientific Track: Redefining Pharmaceutical Innovation from Bench to Bedside

Grand Ballroom

### Innovation in Clinical Trials

**Session chairs** Yufeng Li, Executive Director, Clinical Development, Qilu Pharma

Dongjing Fu, Director, Clinical Development, Janssen R&D

**1:00-1:35 p.m.** Alex Morozov, VP & Head of Digital Health, Global Drug Development, Bristol Myers Squibb

“The Promise of Digital Health: from Clinical Trials to Clinical Practice”

**1:35-2:10 p.m.** Vinay Parikh, Psychology & Neuroscience Professor, Temple University

“Reimagining Neuroscience Drug Development Using a Digital Companion Strategy”

**2:10-2:45 p.m.** Jennings Xu, Director, Data Science Portfolio Management, Janssen R&D

“Data Science Driven Acceleration of the J&J Covid-19 Vaccine Phase III Trial”

## Business Track: Unleashing the Power from Scientific Breakthroughs and Entrepreneurship

Centennial Ballroom I

### Building and Growing a Life Science Company (co-branding with BioKatalyst)

**Session chairs** Seamus Jiang, Managing Director, China/US. Cross-border deals Leader, PwC US

**1:00-3:00 p.m.** Yuhang Zhao, SVP, CGE

Jimmy Hao, Partner & Chair, Fox Rothschild

Dahai Guo, Chairman and CEO, Zennova Pharma

Joanne Jiang, CEO, LeaderMed Group

Panel discussion

## Career Development: Do You Need an Executive Coach?

Centennial Ballroom II

**Session chair** David Cragin, Director, Quality Assurance, Merck & Co., Inc.

**1:00-3:00 p.m.** Marie Leithauser, Executive Coach & Consultant, BioPharma R&D

## SAPA-GP Leadership and Volunteer Awards & Closing Remarks

**3:00-3:10 p.m.** Yongchao Su, President of SAPA-GP 2022; Principal Scientist, Merck & Co., Inc.  
Haichen Yang, President-Elect of SAPA-GP 2022-2023; VP, Clinical Research, Amicus Therapeutics

**3:10-5:00 p.m.** **Networking & Reception**

## SPEAKERS




**Geert Cauwenbergh, Ph.D.**

*Managing Partner*  
Phases 123 L.L.C.

Dr. Geert Cauwenbergh is Managing Partner of Phases123 LLC, a New Jersey based “think-tank”, consulting and advisory firm for biotech and pharmaceutical companies. Phases123 LLC is primarily focused on support of private start-up companies and small to medium size health care companies (organizational- & business development, R&D strategy & planning, corporate strategy & financial planning, investor- & public relations). Until February 2019, Geert Cauwenbergh has been President and CEO of Phio Pharmaceuticals a NASDAQ-listed biotechnology company (PHIO: NASDAQ) that is developing self-delivering interference RNA (RNAi) for immunoncology and adoptive cell transfer therapy. Prior to his involvement in Phio Pharmaceuticals he also founded or co-founded several other privately held companies such as Phases123, Aramis Pharma, Legacy Health Care and Anethon. Through his consulting firm, Dr Cauwenbergh held positions as Chairman & CEO of RHEI Pharmaceuticals (China), managing director of the Center for Medical Innovation (Belgium) and Executive Chairman of ECI Biotech (USA). Prior to founding Phases123 and Aramis LLC, in 2002, Dr Cauwenbergh was Founder, Chairman and CEO of Barrier Therapeutics (BTRX: NASDAQ), a biopharmaceutical company with focus on dermatology drug development. Barrier was acquired by Stiefel Laboratories in 2008, at a moment that the company reached annual revenue of \$45 million. Between 1994 and 2002 Geert held various senior management positions in the Johnson & Johnson Global Consumer Organization and was member of a number of boards within the family of companies of Johnson & Johnson. From 1979 – 1994, Dr Cauwenbergh held various positions in Janssen Pharmaceutica in Belgium, the last one as global Clinical Director for R&D in dermatology and infectious diseases Dr. Cauwenbergh is currently a member of the Board of Directors of Phio Pharmaceuticals (USA) and Legacy Health Care (Switzerland). Over the past 18 years he has been Board member of several private and public companies, including Moberg Pharma, a public dermatology OTC company in Sweden, Phosphagenics, a public delivery platform technology company in Australia, and Cutanea Inc, a US based subsidiary of Maruho, a Japanese dermatology company. Previously he has held Board positions in Intercept (Public - USA), DARA Biosciences (Public - USA), Upstream Biosciences (Public - Canada), Alto Pharmaceuticals (Canada), Ablynx (Public - Belgium) and Euroscreen (Belgium). He currently also serves as Advisor for Economic Diplomacy for the Belgium in the USA. Dr Cauwenbergh has authored > 100 publications, and received his Doctorate in Medical Sciences from the Catholic University of Leuven, Faculty of Medicine, where he also completed his masters and undergraduate work. In 2004 Dr.

Cauwenbergh was inducted in the New Jersey High Tech Hall of Fame.



**Chris Chen, Ph.D.**

*Chief Executive Officer*  
WuXi Biologics

Dr. Chris Chen is currently Chief Executive Officer at WuXi Biologics, leading a 1500-member team providing end-to-end biologics services to global partners. At WuXi he has built a world-class open-access integrated mab discovery, development and manufacturing platform serving full spectrum of companies ranging from virtual companies to 12 large pharma. Under his leadership, WuXi has assembled one of the largest biologics development teams with over 700 scientists enabling 40 global INDs in two years. WuXi is also currently building the largest disposable-bioreactor based state-of-the-art commercial manufacturing facility totaling 30,000L bioreactor capacity in the world. He obtained his dual bachelor degrees of chemical engineering and automation at Tsinghua University, Beijing China and his Ph.D. in chemical engineering at the University of Delaware, US. He then gained valuable experience in process development, manufacturing, technology transfer, process validation, quality, and regulatory in the US, where his previous assignments include director and manager positions of bioprocess development, technical service, and pilot plant operations at Lilly and Merck. Dr. Chen later joined Shanghai Celgene Biopharmaceuticals as Chief Operating Officer, successfully developed a high-titer high-quality commercial process for biosimilar Enbrel, and obtained regulatory approval for the program in China in 2011. He chaired multiple conferences in biochemical engineering and mab development in US and China and is frequently invited to speak at multiple conferences. He is also adjunct professor at Shanghai Jiaotong University. Dr Chen is co-author and co-inventor of 40+ publications and patents.



**David Cragin, Ph.D.,**

**DABT**  
*Director*  
Merck & Co.

Dr. Dave Cragin is a Director in Quality Assurance at Merck & Co. In addition, he teaches risk assessment and critical thinking as Adjunct Professor for Peking University, and Beijing Normal University in Beijing and previously for the University of the Sciences, Philadelphia. Dr. Cragin started teaching managing the risks of a pandemic as part of his course in 2006. He has also taught risk communication across the globe. Dr. Cragin is a Trustee of the Toxicology Education Foundation, is Past-President of the Mid-Atlantic Society of Toxicology, and previously served as a Counselor for PhACT. He received his Ph.D. in Pharmacology and Toxicology from University of California, Davis, his B.S. in Zoology from the

University of Rhode Island, and is a Diplomate of the American Board of Toxicology. He is a Distinguished Toastmaster.



**James Fendrick**

*President & CEO*

Rockland Immunochemical, Inc.

Jim Fendrick, a 30-year veteran of the biotechnology industry, is President and CEO of Rockland Immunochemicals, Inc. and chairman of its Board of Directors. Jim has led Rockland in its growth as a global biotechnology company that focuses on life science research tools and contract research services, positioning the company as a leading expert in antibody and assay development. He continues to lead initiatives around Rockland's global distribution network and its partnerships with major government, academic, and biopharma institutions. Jim is an active board member for the Jefferson Institute for Bioprocessing (JIB), the Montgomery County Development Corporation (MCDC), and a founding member of PHL Art & Life Science (PALS) Initiative. He has partnered professionally and personally with Life Sciences Pennsylvania (LSPA) and the Yellow Springs Art Show. A graduate of Gettysburg College, Jim and his wife, Maureen, reside in Chester County, PA.



**Lora Feng**

*President & CEO*

LFI Solutions, Inc.

Lora Feng is founder/CEO of LFI Solutions, Inc., a management consulting firm specializing in cross border strategies and transactions in the life science industry across North America, Asia, and Europe. She has assisted companies with market entry planning, business development, and advised on transactions valued over \$100M. Prior to this, she worked for Fortune 500 companies including JPM Chase, Citibank, Moody's, Dentsply International in the role of product management, portfolio management, marketing, and finance, where she launched over 50 first in class products, and managed assets up to \$20B. Lora has a MS in Marketing from University of Illinois, USA, MS in Education from Institute of Education in Singapore, and BS in Economics from University of International Business and Economics, Beijing, China. She has completed courses in Financial Investment from Columbia University, Accounting from Stern Business School of NYU, and online courses in biology and immunology.



**Dong-Jing Fu, M.D., Ph.D.**

*Director*

Johnson & Johnson

Dr. Fu is a Director in Neuroscience Clinical Development at Janssen Research and Development. Currently she is the Clinical Leader of the intranasal esketamine development program in patients with treatment resistant depression and major depression at imminent risk for suicide. Since joining Johnson & Johnson in 2005, Dr. Fu has worked on pivotal studies for the treatment of depression, suicidality, schizophrenia, and schizoaffective disorder. She has held positions within Janssen R&D and Medical Affairs directing global clinical trials, leading pharmacogenomics projects in psychiatry, and overseeing a program to support independent medical education in psychiatry. Dr. Fu had prior positions with Eli Lilly and Sequenom involving research and technology development for precision medicine. Dr. Fu has authored publications focused on clinical and pharmacogenomic research of psychiatric diseases and treatments, scale validations, and technology development. Dr. Fu received her PhD in biochemistry from Boston College and a MD from Beijing Medical University.



**Julia Z. Gao, Ph.D.**

*CMC Team Leader*

Bristol-Myers Squibb

Julia Gao is a director, CMC team leadership at BMS where she is responsible for developing and driving the execution of comprehensive, compound-specific CMC development strategies and tactics across the drug substance, drug product, analytical, quality, regulatory and clinical material space. Julia has a Ph.D. in Pharmaceutical Sciences and has nearly 20 years product development experience for early and late-stage assets. She has contributed to the approval of several adult and pediatric products.



**Dahai Guo, MBA**

*Chairman & CEO*

Zenova Pharmaceuticals

Mr. Dahai Guo is successful series entrepreneur who has served as Chairman & CEO over 7 pharmaceutical companies in both US & China. Currently, he is the Chairman & CEO of Zenova Pharma Group, including operations of Zenova LLC in US and Zenova Pharmaceuticals (Chengdu) Inc. in China. In his successful career, he was the Founder & CEO of successful companies such as PuraCap Pharmaceutical LLC. (in US), Chairman & CEO of Humanwell PuraCap Pharmaceutical



(Wuhan) Ltd. (in China), CEO of Epic Pharma (in US), CEO of Puracap International LLC. & CEO of Humanwell USA LLC. etc. Under Mr. Guo's leadership, Zennova & PuraCap Pharmaceutical with its affiliated companies are one of the leaders in specialty pharma & healthcare industry, who has developed, manufactured, and marketed broad range of Branded Rx, Generic Rx and OTC pharmaceutical products in US & the global markets. There are over 80 different drugs and over 400 SKUs selling in US, China, Canada and other countries. It has four US FDA inspected manufacturing and packaging facilities globally. Under Mr. Guo's leadership, PuraCap has been recognized and awarded as "Top Ten Leading Chinese Pharmaceutical Company in Global Market" & "China's Top 100 Gazelle Companies" award. He was the winner of "Entrepreneur of the Year" Aware to Overseas Chinese. Mr. Guo has MBA from Cornell University and M.S. of Biology from Rutgers University, BS from Xiamen University. He also completed distinguish Six-Sigma Black Belt training, awarded by America Society for Quality. Mr. Guo is founding Chairman of BioKatalyst Corp, a non-profit organization whose invited-only members are the top management elites of Chinese Americans crossing healthcare industry. Mr. Guo is honored the Lifetime Award of Distinguished Alumni Of Xiamen University the School of Life Science.



**Jason (Jian) He, Ph.D.**  
*Senior Director*  
 WuXi Biologics

Dr. Jason (Jian) He is a Senior Director of CMC Management based in greater Philadelphia area, Pennsylvania. Jian received his B.S. in Chemistry from Peking University, and Ph.D. in Biochemistry from University of Pennsylvania. Prior to joining Wuxi Biologics, Jian had 14-year experience of large molecule product development in Merck with growing leadership responsibilities. Jian has led assay development functional team to support Merck vaccines and mAbs. In the recent 6 years, Jian has successfully led a couple of Merck's biologics products as CMC lead, governing the integrated process, analytical, and formulation teams through preclinical, clinical and BLA stages.



**Jun He, Ph.D.**  
*Assistant Professor,*  
*department of pathology,*  
*anatomy and cell biology*  
 Thomas Jefferson University

Jun He is an Assistant Professor at Department of Pathology, Anatomy and Cell Biology at Thomas Jefferson University. She had a medical background in environmental medicine, and earned her PhD degree at Thomas Jefferson University. Dr. He is the recipient of a NIH/NCI K99/R00 Pathway to Independence Award, which has been instrumental to establishing her research program. The research areas in Dr. He's lab include non-coding RNA, epigenetic regulation, reactive oxygen species (ROS), extracellular vesicles, and metabolic alteration in tumor initiation, progression, tumor immune response, angiogenesis, and drug resistance. The research goal is to identify novel druggable therapeutic targets for cancer treatment. So far, she has published more than 30 research papers in leading journals such as JECCR, Autophagy, EMBO Report, Environmental Health Perspectives and Oncogene.



**Jimmy Hao, MBA**  
*Partner & Chair*  
 Patent Practice

Mr. Hao is a Partner, Chair of the Patent Practice, and Co-Chair of the Pharma & Biotech practice at Fox Rothschild LLP. With decades of legal experience, Mr. Hao serves clients including Fortune 500 companies, startups, entrepreneurs, investors, and academic institutions on a broad range of legal issues, including patent, trademark, licensing, IP litigations, international, corporate, vc financing, and nonprofit. While focusing on preparation/prosecution of U.S. and foreign patents. He provides a full range of patent law services, including developing and managing worldwide patent portfolios, assisting in patent matters in connection with startups, strategic alliance, technology transfer, corporate transactions, freedom-to-operate, invalidity and non-infringement opinion analysis. Mr. Hao has provided representation to several notable business transactions, including Alexion Pharmaceuticals Inc.'s acquisition of Synageva BioPharma, Humanwell Pharmaceutical Group Corporation's acquisition of Epic Pharma, BMS's acquisition of Amira Pharmaceuticals, licensing and collaboration deals involving major universities and companies. Mr. Hao received a JD from Boston College Law School, a PhD from Columbia University, an MBA from Cornell University, and a BS from Nankai University. He is a co-founder of BioKatalyst, a non-profit organization of Chinese business leaders in commercial areas of biopharmaceutical industry.



**Joanne Jiang, Ph.D. MBA**  
*Chairman & CEO*  
 LeaderMed Group


LeaderMed Group is a global integrated pharmaceutical company, addressing the Asian patient care market. LeaderMed is driving pharma connectivity enabling access to the Pharmerging Markets while improving clinical and financial outcomes. Dr. Jiang developed her leadership skills and financial and product development expertise through her entrepreneurial experience as well as leading global, cross-functional teams in global pharma companies. She led development teams in US, EU and Japan and delivered two blockbuster drugs worldwide. She has intensive experience in

pharmacology and clinical development, integrating marketing plans and regulatory strategy that enables optimal trial design and implementation, which in turn delivers best NDA filing quality and timeline. In 2007, Dr Jiang co-founded Fountain Medical Development, a contract research organization (CRO) offering clinical research services in China, Hong Kong, Korea and Taiwan. FMD became one of the largest CRO in US, China and Asia. Dr. Jiang holds a PhD in pharmacology and toxicology from Indiana University, and an MBA from University of Michigan. Dr. Jiang has been invited to present at numerous medical and drug development conferences nationally and internationally.



**Seamus Jiang, Ph.D.**  
*Managing Director*  
Asia Cross-border Deals (PwC)

Seamus is a Deals Managing Director of PwC US based in Philadelphia with over 20 years of M&A and finance experience in North America and Asia. He has been assisting strategic and financial buyers/sellers in evaluating over 200 M&A and investment transactions with an aggregate deal value of over \$200 billion in a variety of industries including many M&A and capital market projects in the Pharma and Life Sciences sector. In recent years, he has led over 60 U.S./Asia cross-border M&A and investment projects spanning across pre-deal strategy, due diligence execution and post-deal integration and value capture. Seamus earned a B.A. in International Economics from Fudan University and an M.B.A. from Goizueta Business School of Emory University. He is a CFA charter holder and holds CPA licenses in both U.S. and China. Seamus is President of BioKatalyst.



**Marie Leithauser, MS,  
MBA, PCC**  
*Executive Coach*  
BioPharma R&D

Marie is an executive coach with 20 years of experience as a senior leader in BioPharmaceutical R&D. She is a trusted confidante to industry leaders and a sought-after mentor. Marie has seen firsthand the impact that senior leaders have on their organizations and appreciates the importance of a solid and well-communicated strategy, efficient and effectual fonve operations, and authentic and thoughtful leadership. During a coaching engagement, Marie partners with clients to develop greater self-awareness and better understanding of their organizational context, to apply their unique strengths to situational challenges, and to build their own genuine leadership style. Marie encourages clients to experiment with different approaches and behaviors and to help clients move from insight to action. Marie powerfully combines deep intuition, authenticity and her own executive experience to help others uncover their personal and leadership strengths. Marie brings warmth, respectfulness, confidence, and open-

mindfulness to her coaching practice. She possesses a keen ability to grasp complex concepts quickly and challenge assumptions. Prior to coaching, Marie was a senior leader of Research at Bristol Myers Squibb. She was chief of staff to the head of Research, a key contributor to business strategy development, and responsible for operational planning. She led the successful integration of a biotech company into BMS and was a key leader of strategic R&D-wide initiatives. Marie has experience in organizational restructuring, talent management, executive communication, stakeholder engagement, change management, process optimization, and navigating complex matrix organizations. Marie earned a B.S. in Chemistry from Wayne State University, M.S. in Oncology from University of Wisconsin-Madison, and MBA from University of Wisconsin-Milwaukee. Marie is a graduate of Duquesne University's Professional Coaching Certification program and is PCC certified by the International Coach Federation. In addition, she holds certification in the Hogan Assessments as well as CMI (Coaching Mindset Index).



**Derrick Li**  
*Managing Director*  
Baird

Derrick Li is a Managing Director in the Global Investment Banking Group at RW Baird focusing on Biotechnology. Prior to RW Baird, Derrick served as Head of Strategy and Investor Relations for Cellular Biomedicine Group, formerly a NASDAQ-listed, biotechnology company that focuses on cell therapies, helping to lead the company to a management buyout led by Yunfeng Capital and other leading Asian investment firms. Before CBMG, he was a Managing Director in the healthcare investment banking practice at B. Riley Securities. He also spent four years as a Partner at TPP Healthcare, a boutique advisory firm that specializes in cross-border transactions between companies from the U.S. and China. Derrick began his career as an equity analyst at The Royce Funds, a leading small and micro-cap focused investment manager. He holds dual bachelor's degrees in accounting and business administration from Villanova University.



**Yufeng Li, Ph.D.**  
*Executive Director*  
Qilu Pharma

Yufeng Li, PhD, is currently executive director of clinical development at Qilu Pharma. In this role, he oversees the clinical science and translational medicine work for Qilu clinical programs in global development. Yufeng also served clinical research leadership roles in China biotech company Ascentage and Transcenta. Prior to this, Yufeng has been with GlaxoSmithKline, with discovery, translational medicine and clinical development experience in areas of cancer vaccine, immune-oncology and inflammation. Yufeng has been


instrumental in the initiation and expansion of GSK1795091 project from early discovery to clinical investigation. Yufeng was trained at Shanghai Jiao Tong University and UT MD Anderson Cancer Center. His research focus was on immunology and cancer immunotherapy, where he has over 20 scientific publications, 2 patent inventions, and several invited speeches at international conferences. Yufeng is also actively involved in community services including GSK volunteer programs, Mainline Chinese school, and most importantly SAPA-GP. Yufeng is a lifetime SAPA member and currently serves as the Executive Council member of SAPA, leading Scientific Programs; Training and Entrepreneurship.



**Yong Liu, Ph.D.**

*Senior Principal Scientist*  
Merck Research Laboratories

Yong Liu (Ph.D.) is a Senior Principal Scientist in the Division of Analytical Research & Development at Merck Research Laboratories. He has been with Merck for over 20 years in the field of analytical chemistry for small molecules pharmaceuticals, siRNAs, peptides and protein therapeutics. Currently, he is leading a team in providing analytical support for small molecule drug development, serving as the leader for external collaboration in the innovation team of the division, and is a co-coordinator for Center of Measurement Sciences between Merck and Purdue University. He has over 50 publications in the field of separation sciences, mass spectrometry, organic chemistry, pharmaceutical sciences, oligonucleotides and related intracellular deliveries.



**Zhuoming Liu, Ph.D.**

*Faculty Instructor*  
Washington University School  
of Medicine

Dr. Zhuoming Liu came originally from China and earned his PhD in March 2015 at The University of Tokyo, where he studied molecular mechanisms of replication of Herpes Simplex Virus 1. After completing my PhD, he stayed on at the same lab as a postdoctoral to complete my research on herpes. In September 2015, he joined Harvard Medical School as a postdoctoral research fellow, then Washington University School of Medicine as a staff Scientist and currently is working as a faculty Instructor to study host factors required for alphavirus viral entry as well as SARS-CoV-2 S mutational antigenic profiling and evolution to monoclonal and polyclonal antibody by using VSV-Chimera virus. Outside lab, he likes reading and travelling, as well as sports.



**Shan Lu, M.D., Ph.D., MBA**

*Professor*  
University of Massachusetts Medical  
School

Dr. Shan Lu is a full professor with tenure and Director, Laboratory of Nucleic Acid Vaccines (since 1996), Department of Medicine, University of Massachusetts Medical School, Worcester, Mass, USA. Dr. Lu was one of early pioneers in nucleic acid vaccines (DNA and RNA) in early 1990s and advocated the further advancement of this field in the last 3 decades. He promoted the heterologous prime-boost vaccination concept and developed the world first polyvalent DNA/protein HIV vaccine into human clinical studies which showed the robust and broadly cross-reactive immune responses. He is a US board certified physician in internal medicine with 20 years clinical practice experience. He has direct management experience of major NIH funded vaccine development programs including GMP manufacturing and FDA IND filing. He has broad biotech industry collaboration and advisory activities. Dr. Lu is the founding Editor-in-Chief, Emerging Microbes and Infections (EMI), a global leading journal in infectious diseases published by Nature and Taylor & Francis respectively. He is also an active member of editorial boards for Journal of Virology, Current Opinion of Virology, Vaccine, NPj Vaccine, Human Vaccines and Immunotherapeutics. Dr. Lu has been a board member for International Society for Vaccines (ISV) since 2008 and served as ISV president for the term of 2011-2013. He served as Chairs for a wide range of vaccine congresses over the last two decades. He is a Fellow of ISV and a Fellow of ACP (America College of Physicians).



**Louis Liu**

*Esq. Founder/Partner*  
Liu, Chen & Hoffman LLP

Mr. Liu specializes in corporate law and focuses on corporate governance, mergers and acquisitions, equity investment transactions, commercial loans, joint ventures, equity investments, hedge fund and private equity fund formations and commercial agreements. Prior to establishing Liu, Chen & Hoffman LLP, Mr. Liu practiced in prestigious Wall Street and Silicon Valley law firms for more than seven years, where he advised various clients in completing more than 100 corporate transactions totaling more than \$7 billion in value.



**Alex Morozov, M.D., Ph.D.**

*VP and Head of Digital Health*  
Global Drug Development  
Bristol Myers Squibb

Alex Morozov is VP and Head of Digital Health, Global Drug Development at BMS. In this role, Alex manages a team of Digital Health Leads with responsibility to develop, lead, and implement digital health strategy and programs within each therapeutic area to increase the value of the portfolio by enhancing care and reaching broader patient communities. Alex joined BMS in late 2019 as VP and Clinical Team Lead for Opdivo/Yervoy in Oncology Clinical Development. Prior to joining BMS, Alex led global clinical programs spanning early and late phase development in oncology at Pfizer, ImClone/Eli Lilly, as well as at Novartis, contributing to the development of Bavencio, Lorbrena, Cyramza and Jakavi, in addition to spearheading digital innovation initiatives. Alex has a Bachelor's of Science from Massachusetts Institute of Technology and MD-PhD from Albert Einstein College of Medicine. He completed his internal medicine residency at Columbia Presbyterian Medical Center, followed by a medical oncology fellowship at Memorial Sloan-Kettering Cancer Center. After joining industry, Alex served as a volunteer Attending Physician in the Division of Oncology, New York Hospital - Weill Cornell Medical Center.




**Vinay Parikh, MPharm,  
Ph.D., MBA**

*Psychology & Neuroscience  
Professor*  
Temple University

Dr. Parikh is a Psychology and Neuroscience Professor, and Head of the Neurochemistry and Cognition Research Group at Temple University. He also holds an affiliated faculty appointment in the Center for Substance Abuse Research at Lewis Katz School of Medicine. Previously, he served as the Director of Neuroscience Program in the College of Liberal Arts and provided strategic leadership, direction, and guidance for all educational and professional activities in the program. Dr. Parikh's research interests broadly focus on neuromodulation of cognition in health and disease. Through this research, he has made significant contributions to understanding of neural substrates critical for attention and executive functions, and how dysregulation of these processes contribute to the development of mental health and substance use disorders. He has also done research investigating mechanisms of brain remodeling in cognitive aging, which has opened new avenues to develop biomarkers and therapies for age-related dementia and Alzheimer's disease. Prior to joining Temple, he worked as a Research Faculty at the University of Michigan where he pioneered biosensor-based approaches to assess the efficacy of cognition enhancers. Dr. Parikh has served on advisory panels of numerous biomedical research agencies including the NIH, Alzheimer's Association, and Michael J Fox Foundation. He also serve as scientific advisor

for Cerepace DTx Solutions, a digital medicine consulting company.



**Xi Qin, MA, MBA**

*COO/CFO*  
NeuExcell Therapeutics

Mr. Xi Qin is the COO & CFO at NeuExcell Therapeutics, which he joined in 2019. He also served as COO & CFO at Avotres from 2020 and 2021. Previously, Xi was COO & CFO at GENEWIZ, a global leader in genomics services. During his 10-year tenure at GENEWIZ, Xi led the business growth from \$9M to \$120M, expanded the operations from U.S. to China/Europe/Japan with >1,000 team members, and managed its strategic sale to Brooks Automation for \$450M in 2018. He also raised \$20M equity at NeuExcell, \$10M at Avotres and \$50M at GENEWIZ. Xi also serves a Board Director at NeuExcell and a couple of other early-stage biotech companies. Mr. Qin has an MBA in Healthcare Management from Duke University, an MA in Immunology from Harvard University, and a BS in Biochemistry from Peking University.



**Yongchao Su, Ph.D.**

*Principal Scientist*  
Merck & Co, Inc.

Dr. Su is a Principal Scientist at Analytical Research & Development, Merck & Co, Inc. and Adjunct Associate Professor in Colleague of Pharmacy at the University of Texas at Austin and Purdue University. He is a member in Physical Analysis Expert Committee in United States Pharmacopeia (USP), a Board member of Eastern Analytical Symposium (EAS), and Co-vice Chair of Gordon Research Conference (GRC) on molecular structure elucidation. He currently serves in the Editorial Advisory Board for *Molecular Pharmaceuticals*, *Pharmaceutical Research*, and *Journal of Pharmaceutical Sciences*. In 2022, he is a scientific program committee member of National Biotechnology Conference, and the Vice Chair of Career Development Committee in American Association of Pharmaceutical Scientists (AAPS). Dr. Su has contributed over 100 publications in peer-reviewed journals (H-index = 33) on pharmaceutical, biophysical and analytical topics, and several patents on drug developments of Islatravir™ and Keytruda™. He is the current President of SAPA-GP (2021-2022).



**Fang Shen, Ph.D.**  
*Vice President, Research &  
 Translational Biology*  
 Immunome Inc

Fang Shen currently holds the position of Vice President of Research and Translational Biology at Immunome Inc, a publicly-traded biotech company that leverages the information stored in memory B cells to guide our discovery of first-in-class antibody therapeutics directed at potentially novel targets. At Immunome, Fang is responsible for the overall strategy of oncology discovery and oversees the oncology portfolio. Prior to Immunome, Fang served as Associate Scientific Director and Group Leader in the Immunology Discovery Department at Janssen R&D, Pharmaceutical Companies of Johnson & Johnson. As project leads for multiple large molecules and small molecule therapeutics projects, he manages a matrixed team to deliver data packages on target identification & validation, lead characterization, and non-clinical pharmacology studies. He also serves as Discovery Lead for multiple compound development teams and actively contributes to regulatory documentation for clinical studies. He led the biology team of the Anti-TNF $\alpha$ /Anti-IL-17A Duobody (JNJ-61178104) project and successfully pushed it into Phase I clinical trial. Fang received the Janssen R&D Innovation Leadership Award in 2011 and 2013. Prior to Janssen, Fang worked at Genentech for over two years and contributed to the BTK inhibitor (GDC-0853) project and PI3K inhibitor project targeting autoimmune diseases. Fang had his postdoctoral training in Dr. Sarah Gaffen's lab at SUNY Buffalo and is one of the major contributors to the scientific understanding of IL-17 receptor signal transduction. His research work received the Keystone Symposia Scholarship (HHS, NIH & NIAID) in 2005. Fang is the author of multiple patents and has published over 20 journal articles and book chapters.



**Jingsong Wang, Ph.D.**  
*Founder, Chairman & CEO*  
 Harbour BioMed

Dr. Jingsong Wang, is the Principal Founder, Chairman and Chief Executive Officer of Harbour BioMed. Prior to founding this company, Dr. Wang served as Head of China R&D and Head of Translational Medicine, Asia Pacific, at Sanofi. He is a former attending physician and clinical fellow at Harvard Medical School. Dr. Wang received his Ph.D. in Molecular Pharmacology from China Pharmaceutical University and has also completed a Molecular Immunology Research Fellowship at Dr. Laurie Glimcher's laboratory at the Harvard School of Public Health.



**Zixuan (Zoe) Wang Ph.D.**  
*Associate Professor*  
 Thomas Jefferson University

Zixuan (Zoe) Wang received a BS and MS in Genetics and Genetic Engineering from Fudan University in China, and a Ph.D. in Biochemistry and Molecular Biology from University of Louisville. She joined the faculty of the Medical College of Georgia in 2003 and the faculty of the Thomas Jefferson University (TJU) in 2008. Dr. Wang currently is an Associate Professor at TJU and the Scientific Director of the Molecular & Genomic Pathology Laboratory at TJU Hospital. She has over 80 publications in peer-reviewed journals in Pubmed. Her expertise includes molecular infectious diseases, and molecular oncology.



**Stella Xu, Ph.D.**  
*Managing Director*  
 Quan Capital

Dr. Stella Xu is Managing Director of Quan Capital, a life science venture fund with deep expertise and broad experiences in cross-border value creation and global investments. Prior to Quan, Stella was Corporate VP/Site Head of Roche R&D Center China and a core member of the global management team of Roche's Immunology, Inflammation & Infectious Diseases. From 2012-2017, she led the fully integrated team of ~200 scientists to deliver an innovative pipeline from Discovery to global clinical development. She also had extensive global business development experience with Roche Partnering. Stella joined Roche from McKinsey US and worked in biotech R&D earlier in her career. Stella received her Ph.D. in Immunology from Northwestern University, and B.S. in Biophysics from Peking University. Stella currently serves on the Board of Design Therapeutics (Nasdaq: DSGN), HBM Healthcare Investment (SWX: HBMN), Therorna Inc., Walking Fish Therapeutics and Zidan Medical. She was a board member of ARMO BioSciences (Nasdaq: ARMO), NextCure (Nasdaq: NXTC) and Tempest Therapeutics (Nasdaq: TPST).



**Jennings Xu**  
*Director, Data Science  
 Portfolio Management*  
 Janssen Research &  
 Development

Jennings is a director of data science, portfolio management at Janssen R&D, covering data sciences activities across the Infectious Disease and Vaccine Therapeutic Areas, as well as serving as the global data science portfolio lead for the Asia Pacific region. In this role, he has led the data sciences team in supporting COVID-19 vaccine development through predictive modeling of disease spread at a global scale to optimize country

and site selection and activation. These efforts recently won the 2021 Innovative Applications in Advanced Analytics award from the INFORMS society and is a finalist for the 2022 Edelman Award in Operations Research. Prior to his current role, Jennings served as director of healthcare for Quid, an A.I./natural language processing and graph network company and as a consultant at McKinsey & Co. He has been featured at the Deloitte AI Forum, the Harvard Business School Healthcare Conference, and on podcasts such as the Effective Statistician. Previously, Jennings was a Simons Fellow in Computational Neuroscience at the Yale Child Study Center and graduated from Harvard with a degree in Biology.



**Haichen Yang, MD, MA,  
MBA**

*Vice President, Clinical  
Research*  
Amicus Therapeutics

Dr. Yang is the President-elect for Sino-American Pharmaceutical Professionals Association-Greater Philadelphia (SAPA-GP) for year 2022-23. She is an accomplished pharmaceutical executive and recognized clinical expert with more than 25 years of drug development experience in the fields of neurology, psychiatry, pain, and metabolic disorders. She has led or significantly contributed to clinical development that resulted in ten worldwide new drug and indication approvals, including Fycompa®, Keppra® (pediatric), and Luvox CR®. Dr. Yang is currently a Vice President Clinical Research at Amicus Therapeutics directing both small molecule and gene therapy clinical programs. She is previously a Vice President at ICON plc, where she provides strategic consulting services on drug development to top executives of biotech/pharma companies. Before that, she has worked for Eli Lilly, Solvay, UCB, and Eisai with increasing responsibility leading a range of clinical development programs. Dr. Yang has published 2 book chapters, more than 40 articles in peer-reviewed journals, and over 120 international meeting posters. She has been frequently invited to speak at high-profile professional conferences. She also serves as a committee member for multiple drug development societies and industry task forces. Dr. Yang received her medical degree from Peking University Health Science Center (formerly Beijing Medical University) in China. She has a Master's degree in molecular biology from Indiana University Bloomington. She also received a MBA degree from Temple University Fox School of Business.



**Bing Yuan, Ph.D., MBA**  
*Co-founder, chairman & CEO*  
OnCusp Therapeutics

Dr. Bing Yuan holds a Ph.D. in Molecular Biology from Columbia University, an MBA from Cornell University and B.S. of Biochemistry from Nanjing University. He is an entrepreneur and a seasoned business executive in business development and licensing (BD&L), marketing and new product strategy. He has made significant contributions to 13

approved global oncology drugs at various stages of product life cycle, including blockbusters such as Keytruda and Glivec. Before founding OnCusp, he was Chief Strategy and Business Officer at CStone Pharmaceuticals. As a senior executive from the beginning, he helped to build the company from startup to successful IPO and then becoming a commercial stage biopharma. At CStone, he established and managed over 10 departments, such as BD&L, public relations, R&D project management and commercial organization. He successfully reached close to 10 strategic partnerships with Pfizer, Bayer, Blueprint, Agios, EQRx, etc. Before joining CStone in November 2016, he spent 22 years in the USA. He was Executive Director and Global Lead of Oncology BD&L at Merck (MSD), Global Head of Life Cycle Strategy and Executive Director at Novartis Oncology, Global Oncology Marketing Lead at Eisai, and Product Manager at Thermo-Fisher. He successfully led or contributed to over 40 M&A, licensing and Keytruda clinical collaboration deals. As a core member of the global project team (GPT), he played a key role in designing development strategy for 5 oncology drugs. He used to lead Glivec and Afinitor brand life cycle strategy and participated in global launch of Zykadia in ALK+ lung cancer.



**Yan Yuan, Ph.D.**  
*Professor of Microbiology,*  
University of Pennsylvania

Dr. Yan Yuan is a Professor of Microbiology at the University of Pennsylvania (since 1997). He graduated from Shandong University with a bachelor's degree in biology, received his master's degree from Shanghai Institute of Cell Biology, Chinese Academy of Sciences, and his Ph.D. from Baylor College of Medicine. From 1991 to 1996, he was trained as a postdoctoral fellow under Dr. Sidney Altman (a Nobel Prize Laureate in 1989) at Yale University. Dr. Yuan Yan is a virologist and epidemiologist with interest in tumor viruses and their oncogenesis. His laboratory at the University of Pennsylvania has engaged in research on Kaposi's sarcoma virus (KSHV) and Epstein-Barr virus (EBV) for 25 years. His research has resulted in a series of seminal discoveries: 1) For the first time in the world, multiple KSHV immediate-early genes (Immediate-early Genes) was discovered, and their functions were investigated; 2) A number of novel immune evasion strategies by KSHV was elucidated; (3) Research on KSHV DNA replication and virion assembly identified critical targets for antiviral drugs and potential antiviral small molecular compounds were obtained; 4) Recently, Dr. Yuan discovered and proved for the first time in Xinjiang Uyghur population that childhood osteosarcoma was caused by KSHV infection. Dr. Yuan Yan has published more than 70 original research articles in "Science", "Proc. Natl. Acad. Sci. USA", "Journal of Virology", "The Journal of Biological Chemistry", "PLoS Pathogens", etc., and served in the editorial board of "Journal of Virology" and "PLoS Pathogens". Dr. Yuan is also interested in being an entrepreneur engaged in drug


development for treatment of cancer, neovascular eye diseases and infectious diseases.



**Yang Yuan, Ph.D.**

*Senior Principal Scientist*  
Bristol Myers Squibb

Yang Yuan is a Senior Principal Scientist in Drug Metabolism & Pharmacokinetics group at Bristol Myers Squibb. She works as a DMPK project lead in global drug discovery and development team. Prior to joining BMS, she worked at DuPont and FMC as technical leader in global regulatory sciences group as subject matter in drug metabolism/PK with increasing responsibilities. She has involved with regulatory strategies development to support new product registration and product renewal. Yang has received FMC Corporate emerging leader in R&D in 2018 and management award, technical leadership award while at DuPont. Yang has received her Ph.D. in medicinal chemistry with a focus on analytical chemistry from College of Pharmacy, University of Illinois Chicago in 2012. She has served as chair of Delaware Valley Mass Spectrometry group from 2013-2016. She is currently the president elect of SAPA-GP. She actively chairs scientific conferences of ACS/AGRO and ASMS. She has contributed over 20 publications and frequently given presentation and invited seminars in scientific conference. She serves as reviewer to scientific journals such as Journal of Pharmaceutical Analysis, Chromatographia, Journal of Agricultural and Food Chemistry. At BMS, she leads the global business insights and analytics group in PAN Asian Network.



**Yun Zhang, Ph.D.,**

**DABT**

*Drug Safety Team Lead*  
Pfizer

Yun Zhang (YZ), PhD, DABT, is a full-time Drug Safety Team Lead (DSTL) at Pfizer since 2017. Dr. Zhang is an experienced drug developer, as a Project Toxicologist, with over 20+ years of comprehensive experience in non-clinical drug safety assessment in the biopharmaceutical industry (CRO and large pharmaceutical companies). He started his toxicology career with the Southern Research (SRI, a CRO) in 2002 as the SD/Toxicologist on a variety of GLP toxicology studies designed to evaluate non-clinical safety of drug candidates (small molecules, biologics, vaccines, gene therapy, and siRNA). After he switched to large pharmaceutical companies in 2004 (Merck, GSK China, and Pfizer) as part of the drug development team, he has been involved in the entire process of the drug discovery and development and gained broad working experience/knowledge of the drug discovery/development process and knowledge of regulatory processes and guidelines. He has served as the Safety Assessment (SA) Representative on multiple early and late drug development project teams with demonstrated capability of

integrating information across drug development disciplines and influencing program/project directions. As the SA Rep, he is responsible for non-clinical safety program strategy, designing/planning non-clinical safety studies, toxicity risk management, preparation of toxicology regulatory submissions and addressing potential regulatory issues, and participating for review/evaluation of potential licensing candidates. In addition, he has been actively involved in the SAPA, AACT, and RDPAC activities.



**Yuhang Zhao, Ph.D.,**

**MBA**

*Senior adviser*  
China Grand Enterprises

Dr. Yuhang Zhao, received her Doctorate in Molecular Biology from Rockefeller University and her MBA in Finance from NYU Stern Business School. She has extensive experience and knowledge in new product development, registration, and commercialization (both drugs and medical devices). Prior to 2017, Yuhang was a member of Bayer Global Leadership circle and established one of Bayer Pharmaceutical's four Global Clinical Development sites in Beijing, China, and built the Global Strategy function for Consumer Health. Prior to Bayer, she had an unusual career that spanned academia, Wall Street, and Management Consulting. She was one of the first scientist-turned-biotech stock analysts in Wall Street (PaineWebber) in the 1990's and then a management consultant (Deloitte) specializing in R&D and new product launch strategies for Life Science companies. She currently serves on several biotech companies' Board and is a senior adviser to China Grand Enterprises (CGE Inc.)



**Ying-Ying Zhou,**

**Ph.D.**

*Sr. Principal Scientist*  
Merck & Co.

Ying-Ying is a Senior Principal Scientist in the Preclinical Development at Merck Research Laboratories. She had the privilege of working for academia (Columbia University and NYU), government organization (NIH) as well as industry (Schering-Plough and Merck). In her early industry career, Ying-Ying established the GLP hERG laboratory with emerging ICH S7B guideline, and led the safety pharmacology groups to develop various regulatory-required as well as investigative CV and CNS assays to support from the pre-clinical candidate selection to safety assessment for late drug development. She has also served as nonclinical safety representative and overseen various compounds (CRMO/CNS/Oncology etc) from Target ID, candidate selection, through preclinical and clinical development to post-marketing. More recently, she became the China liaison and has been heavily involved in developing China strategy, building the partnership with China functional groups, driving increased communication and interaction with China regulatory bodies and industrial consortium.



Lily Zou, Ph.D., MBA

*Co-founder/CEO*

Degron Therapeutics

Lily Zou is co-founder and CEO of Degron Therapeutics, a Shanghai based start-up biotech company focusing on the discovery and development of targeted protein degradation drugs utilizing its cutting-edge molecular glue technology platform. The company closed its seed round financing in April 2021 and is currently raising Series A capital. Prior to joining Degron, Lily was President and CEO of Fosun Pharma USA and Vice President of Fosun Pharma Group, where she built and grew Fosun Pharma's US business with R&D, regulatory, sales and marketing, and launched over 20 products in the US. Fosun Pharma USA also established an investment arm, FUSION Bioventures, which invests and incubates innovative technologies from leading universities. Lily was Chairman of the Board and Chief Business Officer of Archimmune Therapeutics, a portfolio company of FUSION Bioventures, and board member of Nature's Sunshine Products (NASDAQ: NATR), NovelStar and Glycotest. Prior to Fosun Pharma, Lily held positions in business development, strategy, drug discovery, and portfolio management with increasing responsibilities at large pharmas (Novartis/Sandoz, Wyeth, Millennium), smaller biotechs (ArQule, Coley Pharmaceutical Group), and top management consulting firm (Bain & Co.). Lily holds a Ph.D. in Microbiology and Immunology from Cornell University, an MBA from MIT, and a B.S. in Biology from Beijing University.



# SAPA-GP Leadership Team

Yongchao Su, President (2021-2022)  
Fang Shen, President Immediate Past (2020-2021)  
Haichen Yang, President-Elect (2022-2023)  
Yang Yuan, President-Elect (2023-2024)  
David Cragin, Director of Professional Development  
Cindy Guo, Director of Finance  
Dennis Gross, Strategic Alliance Lead  
Sheng Hu, Director of Operation and Logistics  
Hui Wang, Director of Business Development  
Di Wu, Secretary and Project Manager  
Saisi Xue, Director of Communication  
Xinjun Zhang, Director of IT and Website

## Organizing Committee Members

David Cragin	Lora Feng	Dongjing Fu
Jian He	Jun He	Seamus Jiang
Yufeng Li Yongchao	Tony Shen	Sheng Hu
Su	Hui Wang	Sherry Wang
Di Wu	Saisi Xue	Haichen Yang
Yang Yuan (Chair)	Yan Yuan	Xinjun Zhang
YingYing Zhou	Pengbo Guo	Xiaonan Liu
Yangsi Ou		

## Volunteers

Irene (Yongling) Ai	Qimin Chao	Xi Chen Chen	Yifan Gong
Boying Guo	Xiaoting Ma	Ren Qi Wang	Xiaowei Sun
Juechun Tang	Chen Wang	Ronghui Zhou	Jin Wen
Linxuan Yan	Dahang Yu	Cathy Tang	Daniel Zhu
Wenbin Liu	Jia	Jannis	Yonghong Zhao
Qimin Chao	Yifang Wang		Kai Wang
Liangfen Xiao			

# SPONSORS



# China Dinner @ ASCO Chicago

🕒 6:30 pm – 9:00 pm, June 5th, 2022

📍 Chicago, Illinois

- ▲ 美中抗癌协会成立于2008年，共有2000多海内外国际会员，在美，中，日，澳，香港有办事机构；覆盖国际知名肿瘤药企和学术机构；
- ▲ 共主办，协办50余场高规格国际会议；协办多个肿瘤学术期刊；
- ▲ 发起慈善基金，学术奖项，共资助和培养50余位年青肿瘤学者。



欢迎扫码加入  
美中抗癌协会  
USCACA微信群



Your Trusted CRO Partner in Drug Discovery and Development

Our services include:

- Cell & Gene Therapy
- Biomarkers
- PK/TK - Small & Large Molecules
- Immunogenicity
- Large Molecule Bioanalysis Quantification and Characterization by LC-MS
  
- Ligand Binding Assays
- LC-MS/MS
- Protein Characterization by High Resolution MS
  
- DM, ADME Studies for Early Discovery & Later Development
- AAALAC-accredited Laboratory
- CLIA-licensed
- Sample Storage



Learn more at [AlliancePharmaCo.com](http://AlliancePharmaCo.com)

Contact Us: **610-296-3152**  
17 Lee Boulevard, Malvern, PA 19355



## Professional Multi-omics Services

Genomics, Proteomics and Metabolomics

- Insights from integrated multi-omics data analysis
- Cutting-edge NGS and mass spectrometry platforms
- Applications in drug R&D, agriculture and more



Quality  
Data



Rapid  
Turnaround



Competitive  
Pricing

To learn how BGI's experience can support your research, come talk to us or visit our website: [www.bgi.com/us](http://www.bgi.com/us).

**We Sequence, You Discover**



# BioAngel Incubator

A newly established biotech incubator in Chicago, as a subsidiary of the top biotech incubator (ATLANT) in China, is here to help the startup companies to grow, and provide guidance and technical service during their start-up period.

We also partner with the best Biotech Industrial Park in China, to help entrepreneurs to get funding through different channels (Seed money / VC funds etc.) , realize the entrepreneurship dreams, reduce the risk, increase success rate for new startups.

一家新成立的生物技术孵化器，中国的顶级生物技术孵化器（ATLANT）位于芝加哥的分支，服务于全美。旨在帮助初创公司成长，为早期企业的融资提供指导和技术服务。

和国内的顶级生物创业园区载体有常态化合作，帮助生物科技领域的创业家，提高申报资金的命中率，获取创业资金，把创业梦想落地，降低创业风险，提高创业成功率。

250 Parkway Dr. Ste 150, Lincolnshire, IL 60069

[www.BioAngelinvestment.com](http://www.BioAngelinvestment.com)

[Support@BioAngelinvestment.com](mailto:Support@BioAngelinvestment.com)

773-512-2173



## Biosamples - Clinical Trials

### LET US MANAGE YOUR PROJECT:

- Exclusive access to 50k+ oncology patients, healthy donors, many other conditions
- Global network in Asia, Europe, South America, U.S.
- Scientific expertise
- Competitive rates



See potential enrollment for your study:



PHASE CLINICAL SERVICES  
100 South Bedford Road  
Mount Kisco, NY 10549

[info@phaseclinical.com](mailto:info@phaseclinical.com)  
(800) 838-5285  
[www.phaseclinical.com](http://www.phaseclinical.com)

# Antibody Development Expert

Sino Biological is committed to providing scientific research institutions, biotechnology and pharmaceutical companies with one-stop custom antibody services, from antigen synthesis to antibody generation and manufacturing.

## Diversified Antibody Development Technology



Mouse mAb Development (Hybridoma)



Single B-cell Based Platform




Rabbit mAb Development (Phage Display)



Rabbit pAb Development

## Our Advantages



Free Antigen Evaluation & Immunization Scheme Design

Speedy Immunization option (Mouse/Rabbit): As Fast As 5 Weeks!

Versatile Antibody Screening Platform to Obtain as Many Clones as Required

Integrated Service Packages (e.g., Recombinant Antibody Production)



Sino Biological US Inc.  
Address: 1400 Liberty Ridge Drive, Suite 101, Wayne, PA 19087

Tel: +1-215-583-7898  
Email: cro\_us@sinobiologicalus.com

[www.sinobiological.com](http://www.sinobiological.com)



# WE'RE HIRING!

We are a CRO providing integrated, science-driven, product development services throughout the drug discovery and development process to enable life science companies to achieve their drug development goals.



Be a Key Contributor



Career Advancement



Rewards and Recognition





**GeneLeap Biotech is a global biotech company in the Luye Life sciences portfolio, a leader in China and a new entrant in the US. Our goal is to deliver a best-in-class portfolio of completely novel mRNA and Oligonucleotide based drugs and vaccines.**

## **Our Science**

**We're leveraging recent breakthroughs in human genetics and the transformative success of nucleic acid (mRNA and oligo) . A precision medicine approach is utilized to slow or stop the progression of diseases in the fields of infectious diseases and oncology, as well as other multiple rare and common indications.**

**Company Website: <http://www.geneleapbio.com>**

**Address: 19 Presidential Way, Woburn MA 01801**



**iVIEW Therapeutics Inc.**  
5 Cedar Brook Drive  
Cranbury, NJ 08512  
Tel: 609 773 8580

Website: [www.iviewtherapeutics.com](http://www.iviewtherapeutics.com)

iVIEW Therapeutics Inc. is a clinical-stage biotech company focusing on innovative therapy for the treatment of eye diseases. The company's product pipeline covers novel drug candidates for the treatment of acute conjunctivitis, dry eye, myopia, post cataract anti-inflammation and presbyopia. iVIEW is headquartered at 5 Cedar Brook Drive, Cranbury, New Jersey, with 11,045 sq. fts laboratory and office spaces. iVIEW is currently looking for self-motivated talents to join the company. The company offers **Competitive Salary, Health Insurance including medical, dental and vision care, and Retirement Benefits including 401K plan, Profit Sharing Plan, plus Employee Incentive Plan.** If interested, please send your resume and cover letter to [info@iviewinc.com](mailto:info@iviewinc.com). Opening position available immediately:

### **Director of Formulation & CMC**

- A MS, PhD degree or equivalent in Pharmaceutical Sciences, Chemical Engineering, Chemistry or a related field is required.
- 5-10 years of pharmaceutical industry experience in pharmaceutical formulation or CMC development required.

### **Associate Scientist**

- A BS, MS degree or equivalent in Pharmaceutical Sciences, Chemical Engineering, Chemistry or a related field is required.
- 1-2 years of pharmaceutical industry experience in pharmaceutical formulation development required.

### **Admin Assistant or Office Manager**

- A BS or BA degree or equivalent is required. Candidate with more than 5 years of administration management, basic accounting skills or human resource management experience preferred.

# Accelerating Your Path To IND



≤6 MONTHS      12 MONTHS

wuxibiologics.com

## Industry Leading DNA to IND Timelines

### Quality. Expertise. Speed. Execution.

Our accelerated DNA to IND platform is built upon these cornerstones. This seamless, integrated process enabled over 20 anti-COVID-19 biotherapeutics to enter the clinic. Our proven platform has expedited 267 INDs in just the last few years. We will bring this same effort and success to your drug development efforts.

### Let's Get Started.

Our highly vetted, single-source, expedited biologics platform and timelines:

- Speeds your time-to-clinic
- Removes multiple vendor transitions
- Reduced audits and transaction costs
- Provides single-point project management
- Enabled multiple anti-COVID-19 mAbs to enter the clinic in record breaking time

**WuXi Biologics**  
Global Solution Provider

# OUR INTEGRATED SERVICES

## Humanized Mouse Models

- Humanized Immune Checkpoint Mice
- Immunodeficient B-NDG Mice for Xenograft Studies
- Humanized Cytokine & GPCR Mice
- Humanized Tumor Cell Lines

## Antibody & ADC Discovery

- Fully Human Therapeutic Antibodies, Surrogates, Anti-idiotypic & Bispecific/Multispecific Antibodies
- GPCR & TCRm Discovery Platforms
- Single B Cell Cloning Technology
- Best-In-Class Fully Human Antibody mouse

## Pharmacology Services

- Expertise in Efficacy Evaluation of Novel Therapeutics
- In Vitro Studies, In Vivo Assays, PK, PD, Toxicity Assessments
- Syngeneic Models & Xenograft Tumor Models

## Gene Editing Services

- CRISPR/Cas9-Based Extreme Genome Editing (EGE™)
- ESC-Based Homologous Recombination (Large Fragments)
- Models or Cell Lines

INNOVATIVE SOLUTIONS TO ACCELERATE ANTIBODY DISCOVERY

This meeting brings together the innovators and business leaders to foster collaborations and advance cell and gene therapeutics in Greater Philadelphia area



17-18 Jun, 2022  
Sheraton Valley Forge Hotel  
480 N Gulph Rd  
King of Prussia, PA 19406

### Scientific Track

Discovery, technology & application  
Clinical & regulatory path  
Chemistry manufacturing and control

### CGT in China

Research & collaboration

### @Philly Forum

Market dynamics  
Policy, infrastructure  
Entrepreneurship  
Incubators, manufacture center



# @PHILLY CELL AND GENE THERAPY ANNUAL CONFERENCE

Sponsor and Exhibitor Contact:  
[bd@sapa-gp.org](mailto:bd@sapa-gp.org)